Recombinant CCR2 (Plozalizumab Biosimilar) antibody

Catalog No. ABIN7488078

The Mammalian Cells Monoclonal anti-CCR2 (Plozalizumab Biosimilar) antibody has been validated for ELISA. It is suitable to detect CCR2 (Plozalizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant CCR2 (Plozalizumab Biosimilar) antibody (ABIN7488078)

Target: CCR2 (Plozalizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This CCR2 (Plozalizumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-CCR2 (Plozalizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Plozalizumab Biosimilar - Anti-CCR2, CD192 mAb

Characteristics: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for CCR2 (Plozalizumab Biosimilar)

Target: CCR2 (Plozalizumab Biosimilar)

Target Type: Biosimilar

Background: MLN-1202,anti-CCR2,hu1D9
Plozalizumab is a humanized monoclonal antibody that targets CCR2 chemokine receptors found on the surface of white blood cells such as macrophages and monocytes. Plozalizumab has been investigated to treat Atherosclerosis. CCR2 is supposed to play an important role in the trafficking of monocytes and macrophages to sites of inflammation.

CAS-No: 1610761-46-0